Market revenue in 2023 | USD 203.0 million |
Market revenue in 2030 | USD 371.5 million |
Growth rate | 9% (CAGR from 2023 to 2030) |
Largest segment | C1-inhibitors |
Fastest growing segment | Selective Bradykinin B2 Receptor Antagonist |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist |
Key market players worldwide | CSL Ltd, Takeda Pharmaceutical Co Ltd, Pharming Group, KalVista Pharmaceuticals Inc, Sanquin, BioCryst Pharmaceuticals Inc, Centogene NV Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasma protease c1-inhibitor market will help companies and investors design strategic landscapes.
C1-inhibitors was the largest segment with a revenue share of 53.15% in 2023. Horizon Databook has segmented the China plasma protease c1-inhibitor market based on c1-inhibitors, kallikrein inhibitor, selective bradykinin b2 receptor antagonist covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the China plasma protease c1-inhibitor market , including forecasts for subscribers. This country databook contains high-level insights into China plasma protease c1-inhibitor market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account